Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Shares Acquired by Octagon Capital Advisors LP

Octagon Capital Advisors LP raised its position in Unicycive Therapeutics, Inc. (NASDAQ:UNCY - Free Report) by 16.8% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 10,000,000 shares of the company's stock after purchasing an additional 1,441,000 shares during the period. Unicycive Therapeutics comprises approximately 1.3% of Octagon Capital Advisors LP's portfolio, making the stock its 23rd biggest holding. Octagon Capital Advisors LP owned 9.63% of Unicycive Therapeutics worth $7,942,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. Northern Trust Corp boosted its stake in Unicycive Therapeutics by 142.4% during the 4th quarter. Northern Trust Corp now owns 58,181 shares of the company's stock valued at $46,000 after acquiring an additional 34,183 shares during the last quarter. XTX Topco Ltd lifted its stake in Unicycive Therapeutics by 142.2% in the 4th quarter. XTX Topco Ltd now owns 171,463 shares of the company's stock worth $136,000 after acquiring an additional 100,679 shares in the last quarter. Geode Capital Management LLC grew its stake in shares of Unicycive Therapeutics by 30.3% in the 4th quarter. Geode Capital Management LLC now owns 524,487 shares of the company's stock valued at $417,000 after buying an additional 122,089 shares in the last quarter. Acuta Capital Partners LLC lifted its holdings in Unicycive Therapeutics by 16.4% in the 4th quarter. Acuta Capital Partners LLC now owns 2,303,000 shares of the company's stock worth $1,829,000 after purchasing an additional 323,801 shares during the last quarter. Finally, Vivo Capital LLC grew its stake in shares of Unicycive Therapeutics by 123.0% in the fourth quarter. Vivo Capital LLC now owns 9,970,152 shares of the company's stock worth $7,918,000 after acquiring an additional 5,500,000 shares during the last quarter. 40.42% of the stock is currently owned by hedge funds and other institutional investors.

Unicycive Therapeutics Stock Up 2.8%

NASDAQ:UNCY opened at $0.57 on Tuesday. The business's 50-day moving average price is $0.59 and its two-hundred day moving average price is $0.61. Unicycive Therapeutics, Inc. has a twelve month low of $0.20 and a twelve month high of $1.16. The stock has a market cap of $68.22 million, a P/E ratio of -0.58 and a beta of 2.14.

Unicycive Therapeutics (NASDAQ:UNCY - Get Free Report) last issued its quarterly earnings results on Thursday, March 27th. The company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.13). On average, equities research analysts expect that Unicycive Therapeutics, Inc. will post -0.23 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on the stock. Guggenheim started coverage on shares of Unicycive Therapeutics in a research report on Monday, April 21st. They set a "buy" rating and a $6.00 target price on the stock. HC Wainwright reissued a "buy" rating and issued a $7.50 price target on shares of Unicycive Therapeutics in a report on Friday, April 11th.

Unicycive Therapeutics Profile

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.